BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liang J, Liu Z, Wei X, Zhou L, Tang Y, Zhou C, Wu K, Zhang F, Zhang F, Lu Y, Zhu Y. Expression of FSCN1 and FOXM1 are associated with poor prognosis of adrenocortical carcinoma patients. BMC Cancer 2019;19:1165. [PMID: 31783819 DOI: 10.1186/s12885-019-6389-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Wu K, Liu Z, Liang J, Zhang F, Zhang F, Wang Y, Lia T, Liu S, Zhu Y, Li X. Expression of glucocorticoid receptor (GR) and clinical significance in adrenocortical carcinoma. Front Endocrinol 2022;13:903824. [DOI: 10.3389/fendo.2022.903824] [Reference Citation Analysis]
2 Jia Y, Li J, Wang J, Luo T, Jing X, Zhao H, Broggi G. Study on the Function and Mechanism of miR-585-3p Inhibiting the Progression of Ovarian Cancer Cells by Targeting FSCN1 to Block the MAPK Signaling Pathway. Analytical Cellular Pathology 2022;2022:1-12. [DOI: 10.1155/2022/1732365] [Reference Citation Analysis]
3 Li Z, Fei H, Lei S, Hao F, Yang L, Li W, Zhang L, Fei R. Identification of HMMR as a prognostic biomarker for patients with lung adenocarcinoma via integrated bioinformatics analysis. PeerJ 2021;9:e12624. [PMID: 35036134 DOI: 10.7717/peerj.12624] [Reference Citation Analysis]
4 Grisanti S, Cosentini D, Sigala S, Berruti A. Molecular genotyping of adrenocortical carcinoma: a systematic analysis of published literature 2019-2021. Curr Opin Oncol 2022;34:19-28. [PMID: 34669649 DOI: 10.1097/CCO.0000000000000799] [Reference Citation Analysis]
5 Wang L, Lyu Y, Li Y, Li K, Wen H, Feng C, Li N. ASXL1 promotes adrenocortical carcinoma and is associated with chemoresistance to EDP regimen. Aging (Albany NY) 2021;13:22286-97. [PMID: 34536950 DOI: 10.18632/aging.203534] [Reference Citation Analysis]
6 Kiesewetter B, Riss P, Scheuba C, Mazal P, Kretschmer-Chott E, Haug A, Raderer M. Management of adrenocortical carcinoma: are we making progress? Ther Adv Med Oncol 2021;13:17588359211038409. [PMID: 34484430 DOI: 10.1177/17588359211038409] [Reference Citation Analysis]
7 Wang Y, Zhang F, Wu D, Wang Q, Nie L, Yu J. A novel circ_0099999/miR-330-5p/FSCN1 ceRNA crosstalk in pancreatic cancer. Autoimmunity 2021;54:471-82. [PMID: 34409897 DOI: 10.1080/08916934.2021.1963958] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Fu Y, Sun S, Bi J, Kong C, Yin L. Expression patterns and prognostic value of m6A RNA methylation regulators in adrenocortical carcinoma. Medicine (Baltimore) 2021;100:e25031. [PMID: 33725886 DOI: 10.1097/MD.0000000000025031] [Reference Citation Analysis]
9 Mizdrak M, Tičinović Kurir T, Božić J. The Role of Biomarkers in Adrenocortical Carcinoma: A Review of Current Evidence and Future Perspectives. Biomedicines 2021;9:174. [PMID: 33578890 DOI: 10.3390/biomedicines9020174] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Liu H, Zhang Y, Li L, Cao J, Guo Y, Wu Y, Gao W. Fascin actin-bundling protein 1 in human cancer: promising biomarker or therapeutic target? Mol Ther Oncolytics 2021;20:240-64. [PMID: 33614909 DOI: 10.1016/j.omto.2020.12.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]